Metraipolis › archive › dc_07c74cfb5065

Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan — Europe PMC PMID:42437898

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42437898
DOI
10.1186/s12885-[numero omesso]-4
License (as archived)
solo-consultazione
Archived
2026-10-18T07:31:09.680Z
SHA-256 of the archived text
c9f2811ac48f62930a5598f8d74623b5009e849315658a9b215a5a77bded2f7e
Stable URL of this page
https://metraipolis.com/documento/dc_07c74cfb5065

How to cite

Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan — Europe PMC PMID:42437898 — Europe PMC (en), https://europepmc.org/article/MED/42437898 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_07c74cfb5065 (Metraipolis archive dc_07c74cfb5065, sha256 c9f2811ac48f62930a5598f8d74623b5009e849315658a9b215a5a77bded2f7e)
BibTeX
@misc{dc07c74cfb5065,
  title = {Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan — Europe PMC PMID:42437898},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42437898},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_07c74cfb5065; sha256 c9f2811ac48f62930a5598f8d74623b5009e849315658a9b215a5a77bded2f7e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42437898. Agents can read the archived copy with the MCP tool read_document.